Integer Holdings Corporation

Integer Holdings Corporation

ITGRNYSE / NASDAQHealthcareMid cap

$126.97+$0.27 (+0.2%)

Last close · Data as of Nov 16, 2026

Market cap
$3.1B
P/E
30.6x
EV / EBITDA
15.2x
Revenue
$1.9B
Net margin
5.5%
ROCE
7.5%

Hidden because the last close is more than three trading days older than the latest prices of its class.

Integer Holdings Corporation price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 16 Nov 2026 close.

1M
Stale
3M
Stale
6M
Stale
1Y
Stale
5Y
Stale
  • Hidden because the last close is more than three trading days older than the latest prices of its class.

52-week range

Day change +$0.27 (+0.2%) from $127 to $127 · Last close Nov 16, 2026

Best weekday to invest, historically

The same weekly amount in ITGR, bought on each weekday since 2021.

News & filings

What Integer Holdings filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernReturn on equity of 5.9% against a peer median of 7.2%.

Strengths (1)

  • Operating margin of 12.9% against a peer median of 6.7%.
  • Prices are as of 16 Nov 2026; price-based points are paused until newer prices arrive.

Prices to the 16 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Integer Holdings Corporation operates as a medical device contract development and manufacturing company in the United States, Costa Rica, Puerto Rico, Ireland, and internationally.

Read moreShow less

Integer Holdings Corporation operates as a medical device contract development and manufacturing company in the United States, Costa Rica, Puerto Rico, Ireland, and internationally. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; implanted medical devices, implanted leads, procedure accessories, and external devices; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; orthopedics, minimally invasive surgery, and general surgery devices; and portable medical devices, including patient monitoring, ventilators, portable defibrillators, portable ultrasound, and X-Ray machines. Furthermore, the company provides medical technologies; supplies medical stamped components, and shallow and deep draw casings and assemblies; and epicardial pacing leads. It serves multi-national original equipment manufacturers and affiliated subsidiaries in the cardiac rhythm management, neuromodulation, orthopedics, cardio and vascular, and advanced surgical and portable medical markets. The company provides its products under the Greatbatch Medical and the Lake Region Medical brands. The company was formerly known as Greatbatch, Inc. and changed its name to Integer Holdings Corporation in July 2016. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.

Sector
Healthcare
Shares outstanding
34.7M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$3.1B
P/E
30.6x
P/B
1.8x
EV / EBITDA
15.2x
EV / Sales
2.4x
P/S
1.7x
52-week high
$126.97
52-week low
$67.10

Profitability

Operating margin
12.9%
Net margin
5.5%
EBITDA margin
15.8%
ROE
5.9%
ROCE
7.5%
ROA
3.0%
Asset turnover
0.54

Growth

Revenue
$1.9B
Revenue growth, 1Y
8.0%
Revenue CAGR, 3Y
11.7%
Net profit growth, 1Y
-14.3%
Free cash flow
$105.1M

Solvency

Current ratio
3.32
Debt / Equity
0.75
Debt / Assets
0.38
CFO / Net profit
1.91
Cash / Market cap
0.5%

Where the revenue went

Of every $100 of FY2025 revenue, $6 was left as net income.

Integer Holdings Corporation income statement flow, FY2025
Integer Holdings Corporation income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$1.4B
RevenueGross profit$500.4M
Gross profitResearch and development$49.5M
Gross profitSelling, general and administrative$211.8M
Gross profitOther operating expenses$0.00
Gross profitOperating income$239.1M
Operating incomePretax income$125.4M
Operating incomeInterest and other expense$113.7M
Pretax incomeTax and other$22.6M
Pretax incomeNet income$102.8M

Revenue and net profit

Revenue grew 8.0% in FY2025; net profit is the dashed line.

Integer Holdings Corporation revenue and net profit by fiscal year
Integer Holdings Corporation revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$1.3B$66.4M
FY2023$1.6B$90.7M
FY2024$1.7B$119.9M
FY2025$1.9B$102.8M

Cash flows

FY2025: $196.1M from operations, $105.1M free after investment (dashed).

Integer Holdings Corporation operating and free cash flow by fiscal year
Integer Holdings Corporation operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$116.4M$41.7M
FY2023$180.2M$60.3M
FY2024$205.2M$99.8M
FY2025$196.1M$105.1M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$1.9B+8.0%1Y
EBITDA
$292.4M-6.0%1Y
Net profit
$102.8M-14.3%1Y
Cash from operations
$196.1M-4.4%1Y
Free cash flow
$105.1M+5.3%1Y
Revenue CAGR, 3Y
11.7%
Net profit CAGR, 3Y
15.7%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$1.9B$292.4M$102.8M$105.1M5.9%+8.0%-14.3%

Monthly returns

Month-by-month returns of ITGR across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$3.4B
Liabilities$1.7B
Equity$1.7B
Paid-in capital$771.2M
Retained earnings$994.1M
Treasury stock$76.9M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; ITGR highlighted.

P/E against peers

ITGR trades at 30.6x earnings against a peer median of 19.0x (a 61% premium).

Not shown (no positive earnings and no EV / Sales): Arcus Biosciences, Inc., Supernus Pharmaceuticals, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Integer Holdings CorporationITGRthis companyP/E ↑ premium$3.1B30.6x1.8x5.9%15.2x
ACADIA Pharmaceuticals Inc.ACAD$3.7B9.5x3.0x31.9%30.8x
Organon & Co.OGN$3.5B18.8x4.7x24.9%9.0x
ICU Medical, Inc.ICUI$3.4B4607.1x1.6x0.0%14.7x
Concentra Group Holdings Parent, Inc.CON$3.2B19.2x8.1x42.3%12.7x
Arcus Biosciences, Inc.RCUS$3.1B-8.8x4.9x-55.9%-8.9x
National HealthCare CorporationNHC$2.9B24.5x2.7x11.2%13.7x
Privia Health Group, Inc.PRVA$2.7B117.5x3.7x3.1%50.4x
Supernus Pharmaceuticals, Inc.SUPN$2.6B-67.3x2.4x-3.6%58.9x
Peer median—19.0x3.3x7.2%14.2x

Year-to-date ROI

ITGR since 1 January, against earlier years.

Historical volatility

ITGR's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Integer Holdings Corporation operating margin by fiscal year
Integer Holdings Corporation operating margin by fiscal year
DateOperating margin
FY20229.6%
FY202311.2%
FY202412.8%
FY202512.9%
LineFY2025
Cost of revenueCost Of Revenue$1.4B
Gross profitGross Profit$500.4M
Operating expensesOperating Expense$261.3M
Research and developmentResearch And Development$49.5M
Selling, general and administrativeSelling General And Administration$211.8M
Other operating expensesOther Operating Expenses—
Total expensesTotal Expenses$1.6B
Pretax incomePretax Income$125.4M

Learn while you research

Academy chapters picked for Integer Holdings Corporation and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 30.6, learn when high multiples are justified.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →